



ECC2015

Sun 27 Sep

Hall D1 - 14:45 - 16:55

General

Presidential Session: Presidential Session II

Chair: E.G. de Vries (Netherlands)

Chair: R. Marais (United Kingdom)

14:45 Pezcoller Foundation- ECCO Recognition for Contribution for Oncology Award
Awardee: K. Meier (Germany)

15:15 ESMO Hamilton-Fairly Award
Awardee: C.J. Punt (Netherlands)

15:45 BEST ABSTRACT: The impact of pathological factors on long-term local control in the EORTC boost no-boost trial
Speaker: C. Vrieling (Switzerland)

15:55 Discussant : J. Yarnold (United Kingdom)

16:05 LATE-BREAKING ABSTRACT: Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
Speaker: J. Yao (USA)

16:15 LATE-BREAKING ABSTRACT: 177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial
Speaker: P. Ruszniewski (France)

16:25 Discussant : E. Grande (Spain)

16:35 BEST ABSTRACT: The interval between primary melanoma excision and sentinel node biopsy (SNB) does not affect survival; regardless of SNB status – an EORTC Melanoma Group study
Speaker: C. Oude Ophuis (Netherlands)

16:45 Discussant : P. Naredi (Sweden)